BRIEF-Resverlogix wins Health Canada nod to test Fabry disease drug

* Resverlogix- received approval from health canada, therapeutic products directorate, to proceed with clinical trial with lead compound apabetalone in patients with fabry disease Source text for Eikon: Further company coverage: